Drugs / NNC0247-0829
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04010786 | Jul 2019 → Jun 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0247-0829 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04010786 ↗ |
| Route | Subcutaneous | “Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin.” NCT04010786 ↗ |